An independent editorial comparison of Hers and Ro, two subscription telehealth brands in the GLP-1 weight-management space. It examines how each program is structured, how their medication and pricing models differ, and the pathway-level genetic variables neither platform maps before prescribing.

Hers leads with clinical telehealth while Noom leads with behavior-change coaching and treats medication as an add-on. This independent PlexusDx review compares the two philosophies, shows where the medicine fits in each, and turns to a genetic variable that no tracking app can log.

This independent editorial comparison of Hers and Hims examines two subscription brands run by the same parent company, explaining why the storefronts are separated, how their published plans differ, why the GLP-1 pharmacology stays identical across both, and the genetic context neither one maps.

This independent single-brand editorial overview examines the Hers weight-loss program on its own terms: how the subscription model works, how it dispenses brand-name or compounded GLP-1 medication, how to read its variable pricing, and the pathway-level genetic context the program does not address.

Understanding what a telehealth GLP-1 program costs means understanding what drives the price, not chasing a single number. This independent editorial review breaks down how Hers structures its fees, the cash-pay reality, and a cost most programs never account for.

The subscription model is what actually defines the Hers experience, from intake to refills. This independent editorial review explains how the telehealth membership is structured, what it typically includes, how fulfillment works, and the genetic context it does not cover.

Where does a telehealth brand like Hers sit within the broader peptide and GLP-1 landscape? This independent editorial overview maps the compounds such programs can dispense, how prescriptions and fulfillment work, and the peptide genetics no telehealth service maps.

This independent editorial review focuses on Mounjaro and its active compound tirzepatide, the branded-versus-compounded distinction, the SURMOUNT trial evidence, and the pathway-level genetics that sit beneath any dual-agonist decision in a program like Hers.

Instead of quoting a single price, this independent editorial review breaks down how Hers is priced: the subscription mechanics, what a monthly charge bundles, the factors that move the total, and how PlexusDx lists its own protocol pricing transparently up front.

Zepbound is a branded tirzepatide product, which complicates what "Hers Zepbound" can mean. This independent editorial review clarifies branded versus compounded tirzepatide, walks through the Hers program workflow, and covers the upstream genetic variable.

Tirzepatide is a dual GIP/GLP-1 agonist, mechanistically distinct from the single-pathway GLP-1 drugs it is often grouped with. This independent editorial review explains how a Hers telehealth program handles tirzepatide, the branded-versus-compounded question, the SURMOUNT trial evidence, and the upstream genetic layer that sits underneath any protocol.

Semaglutide is the active molecule sitting behind several familiar brand names. This independent editorial review explains how a Hers telehealth program routes a semaglutide prescription, what the 503A compounding pathway involves, what the trial record says, and where genetics ultimately fits in.

Searches for "Hers Ozempic" often blur a branded drug with a compounded pathway. This independent editorial review explains what a Hers semaglutide program can actually prescribe, how the telehealth workflow operates, and the upstream genetic context that no prescription captures on its own.

This independent editorial review walks through the Hers GLP-1 program, from intake and eligibility to how a prescription is written and filled, the trial evidence behind the compounds, and the genetic groundwork that sits beneath any GLP-1 decision.

The Hers weight-management program combines medication options with a telehealth service model. This independent editorial review explains how the approach works, which medications it can involve, the provider and pharmacy structure, and the genetic groundwork any protocol rests on.

Hers accepts HSA/FSA via reimbursement (pay with regular card, submit receipt). PlexusDx accepts HSA/FSA card payment at checkout where your plan permits, with no membership fee — protocols from $129/mo, all 50 states.

Eight month-to-month GLP-1 providers compared against PlexusDx Weight Management Protocols on real annual cost, separate membership fees, intro-price cliffs, and genetic baseline. PlexusDx Microdose at $129/mo flat, Semaglutide Injection $189, Tirzepatide Injection $289, GLP-Squared $289 — all cash-pay, no membership.

Which Wegovy providers actually let you swipe your FSA card at checkout vs. file for reimbursement? NovoCare Pharmacy and LifeMD verified for direct-card payment; Hims, Hers, and Ro are reimbursement-first. Plus what to do when your FSA balance runs out and PlexusDx Semaglutide Injection at $189/mo month-to-month, or from $149/mo on the 6-month plan becomes the flat cash-pay reframe.

MEDVi vs Hers vs PlexusDx in 2026: real annual cost math, compounded vs FDA-approved branded medication source, tirzepatide availability across all three, cancellation and refund policy differences, and where the Precision Peptide Genetic Test fits when GLP-1 response varies by GIPR, FTO, MC4R, and TCF7L2 variants.

Florida residents can legally start GLP-1 telehealth in days under Statute §456.47. We compare MEDVi, Ro, Walgreens, and the PlexusDx Microdose GLP-1 Protocol from $129/mo — with a genetic baseline option no other Florida provider offers.